Hikma buys potential Epipen rival from troubled InsysUK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic Share XHikma buys potential Epipen rival from troubled Insyshttps://pharmaphorum.com/news/hikma-buys-potential-epipen-generic-from-insys/
Pfizer confirms generic medicines merger with MylanPfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that Share XPfizer confirms generic medicines merger with Mylanhttps://pharmaphorum.com/news/pfizer-confirms-generic-medicines-merger-with-mylan/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Mylan reports lower than expected earningsMylan has reported lower than expected full year earnings and 2019 forecasts, thanks partly to delays in its Share XMylan reports lower than expected earningshttps://pharmaphorum.com/news/mylan-reports-lower-than-expected-earnings/
FDA finally approves Mylan’s Advair genericThe FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler, after years of Share XFDA finally approves Mylan’s Advair generichttps://pharmaphorum.com/news/fda-finally-approves-mylans-advair-generic/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
Pfizer hit by UK Supreme Court ruling on Lyrica patentPfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to Share XPfizer hit by UK Supreme Court ruling on Lyrica patenthttps://pharmaphorum.com/news/pfizer-hit-by-uk-supreme-court-ruling-on-lyrica-patent/
Mylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedMylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price Share XMylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedhttps://pharmaphorum.com/news/mylan-and-fujifilm-biosimilar-approved/
Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drugAmgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar Share XAmgen faces first Neulasta biosimilar rival as FDA approves Mylan drughttps://pharmaphorum.com/news/amgen-neulasta-biosimilar-fda-mylan-fulphila/
